SARS-CoV-2 vaccination in IBD: more pros than cons - Université de Lorraine
Article Dans Une Revue Nature reviews. Gastroenterology & hepatology Année : 2021

SARS-CoV-2 vaccination in IBD: more pros than cons

Résumé

Data on the efficacy and safety of SARS-CoV-2 vaccines are now available, but evidence for these vaccines in those who are immunocompromised (including patients with inflammatory bowel diseases) are lacking. As vaccination begins, questions on advantages and disadvantages can be partially addressed using the experience from other vaccines or immune-mediated inflammatory disorders.

Dates et versions

hal-03421547 , version 1 (09-11-2021)

Identifiants

Citer

Ferdinando D’amico, Christian Rabaud, Laurent Peyrin-Biroulet, Silvio Danese. SARS-CoV-2 vaccination in IBD: more pros than cons. Nature reviews. Gastroenterology & hepatology, 2021, 18 (4), pp.211-213. ⟨10.1038/s41575-021-00420-w⟩. ⟨hal-03421547⟩
23 Consultations
0 Téléchargements

Altmetric

Partager

More